Interestingly, a chromosomal translocation-induced ALK activation has been identified in 3–5% of non–small cell lung cancer (NSCLC) patients, and is clinically linked to a more aggressive phenotype. This evidence concerns the gene ALK and non-small cell lung carcinoma.